
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc is projected to achieve approximately $32 million in top-line revenue for 2025, with an anticipated increase to $130.4 million in 2026, indicating robust growth potential. The favorable market access situation is expected to improve over the coming months, which could further enhance revenue forecasts. Additionally, the company's pipeline assets, including gene therapies for rare genetic diseases, are positioned to drive significant upside, reinforcing a positive outlook on its financial trajectory.
Bears say
Abeona Therapeutics faces several significant risks that contribute to a negative outlook on its stock. The potential for slower than projected market uptake of its key product, pz-cel, in the United States raises concerns about revenue generation, while challenges in optimizing the product's value in international markets add further uncertainty. Additionally, setbacks in the company's earlier-stage pipeline programs and the risk of long-term dilution could negatively impact investor confidence and financial stability.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares